Finalists announced for NIH's RADx® Tech Fetal Monitoring Challenge - CIMIT MAIN

Responsive Image
The FDA has approved the first rapid hepatitis C virus test for the U.S. market that can be used in patient care settings. The test, which was validated in part by the NIH RADx Tech program with funding from CDC, can provide results in about one hour, meaning patients with a positive test can begin treatment right away. We're honored to have been a part of the journey behind this important milestone! 

Learn more about this game changer for hepatitis C diagnosis >

Programs and Offerings

null Finalists announced for NIH's RADx® Tech Fetal Monitoring Challenge

NIH awards interim prizes in fetal diagnostic and monitoring technology competition

The National Institutes of Health has announced the finalists in its competition to accelerate the development of diagnostic and monitoring technologies to improve fetal health outcomes focusing on low-resource settings. 

The National Institute of Biomedical Imaging and Bioengineering (NIBIB), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), and the Bill & Melinda Gates Foundation partnered to launch the RADx® Tech Fetal Monitoring Challenge in September 2023. The multi-phased competition aims to address the causes of fetal morbidity and mortality, including the estimated 2 million incidences of stillbirth that occur globally each year, with over 24,000 that occur in the United States alone. Novel and accessible technologies are needed to enable earlier and more accurate diagnosis, detection, and monitoring of fetal health status.

Read More >

News and Events

Connect with Us

Our Lasting Impact

As an early pioneer in managing translational research, Cimit has directly supported over 1,200 innovator teams and reviewed or consulted on over 5,000 ideas since our founding in 1998.

We work collaboratively with healthtech innovators, entrepreneurs, and institutions to ultimately make a positive impact on patient care across the globe. We streamline pathways to progress through our efficient processes, established systems, and unparalleled market expertise.